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Abstract IGF-II plays an important role in growth and
development of vertebrates and is highly expressed in adult
salmon liver. In the present study, we demonstrate that a liver-
enriched transcription factor, hepatocyte nuclear factor 3L
(HNF-3L), is an activator of the chum salmon IGF-II gene.
Multiple binding sites for HNF-3L were identified within the 5P-
UTR using electrophoretic mobility shift assays and mutation of
these sites prevents binding of HNF-3L. In transient transfection
assays it was shown that mutation of the HNF-3L binding sites
results in a substantial decrease of HNF-3L-activated salmon
IGF-II gene expression. This is the first identified transcription
factor that is functionally involved in the regulation of fish IGF-
II expression.
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1. Introduction
Insulin-like growth factor II (IGF-II) is a small mitogenic
peptide belonging to the insulin family of peptides, sharing
common structural features. Members of the insulin family
are present in vertebrates, as well as in some invertebrate
species. In the two decades that follow the discovery of
IGF-II protein [1] massive data on the structure, function
and the regulation of expression of mammalian IGF-II genes
were obtained (for a review [2]). Only recently was the ¢rst
¢sh IGF-II cDNA isolated [3]. Since then, IGF-II cDNAs for
other ¢sh species were obtained, and the IGF-II gene struc-
tures were characterized for chum salmon [4], barramundi [5],
tilapia [6], and rainbow trout [7]. The nucleotide sequence of
the pu¡er¢sh IGF-II gene has been reported as well (Gen-
Bank accession number AL021880). However, the function
of IGF-II as well as the regulation of expression of the
IGF-II gene in ¢sh are still poorly understood. No transcrip-
tion factors have been demonstrated to be functionally in-
volved in transcription activation of ¢sh IGF-II genes. High
levels of endocrine IGF-II are produced in the liver and thus
it seems probable that IGF-II gene expression is activated by
liver-speci¢c transcription factors.
The aim of this study is to investigate whether members of
the liver-enriched transcription factors family hepatocyte nu-
clear factor 3 (HNF-3) are capable of enhancing the activity
of the promoter of the chum salmon (Oncorhynchus keta)
IGF-II gene. HNF-3 belongs to the HNF-3/forkhead family
of transcription factors, that function as activators of gene
expression [8]. Members of this transcription factor family
that share a highly conserved DNA binding domain have
been described in organisms from yeast to mammals [9].
The zebra¢sh ortholog of mammalian HNF-3L, Axial, can
activate the zebra¢sh sonic hedgehog gene promoter, and in-
terestingly, rat HNF-3L can also activate this promoter sug-
gesting that not only a structural relation between these tran-
scription factors exists, but also a functional homology
[10,11]. In the present paper we show for the ¢rst time that
the liver-enriched transcription factor, HNF-3L, can activate
chum salmon IGF-II transcription by binding to multiple sites
located in the 5P-UTR of the gene.
2. Materials and methods
2.1. Materials and reagents
Polymerase chain reactions were performed using the PCR kit for
Pfu DNA polymerase (Stratagene, La Jolla, CA, USA). Restriction
enzymes, T4 DNA ligase, Klenow fragment of DNA polymerase I,
and T4 polynucleotide kinase were obtained from Amersham Phar-
macia Biotech (Uppsala, Sweden) and New England BioLabs (Bev-
erly, MA, USA). Radioactive isotopes [K-32P]dCTP (3000 Ci/mmol),
and [Q-32P]dATP (3000 Ci/mmol) were obtained from New England
Nuclear Corp. (Boston, MA, USA).
2.2. Oligonucleotides
Oligonucleotides used for EMSA experiments, PCR, and for muta-
genesis were synthesized by Genosys Biotechnologies Inc., UK.
AP3HNF3, 5P-GGACAGCCTCTCACTCAACATCTCTATAGC-
3P ; AP3RHNF3, 5P-GCTATAGAGATGTTGAGTGAGAGGCTG-
TCC-3P ; AP4HNF3, 5P-CCTCACCAACTGGGAAACTAACTCAA-
CTGC-3P ; AP4RHNF3, 5P-GCAGTTGAGTTAGTTTCCCAGTTG-
GTGAGG-3P ; AP5HNF3, 5P-GCAACCTCTCCAACCAAATATA-
ACGCTCAA-3P ; AP5RHNF3, 5P-TTGAGCGTTATATTTGGTTG-
GAGAGGTTGC-3P ; APMAB, 5P-CAGCCTCTCACGGGGCATC-
TCTATAGCCCTCACCAACTGGGGGGGTAACTCAACT-3P ; AP-
MABR, 5P-AGTTGAGTTACCCCCCCAGTTGGTGAGGGCTAT-
AGAGATGCCCCGTGAGAGGCTG-3P ; APMBC, 5P-CACCAAC-
TGGGGGGGTAACTCAACTGCAACCTCTCCAACGGGGTATA-




2.3. Plasmid constructs and mutagenesis
The sIGF-II luciferase constructs contain the chum salmon IGF-II
gene promoter sequences from 3912 to 34 (pSla900) and 3299 to 34
(pSla300), relative to the ATG translation initiation codon [4], fused
to the ¢re£y luciferase gene-containing expression vector pSla3 [12].
Site-directed mutagenesis of the HNF-3L sites in the sIGF-II-spe-
ci¢c sequence was performed according to the manufacturer’s instruc-
tions, using the Altered Sites II in vitro mutagenesis kit from Promega
(Madison, WI, USA). Brie£y, a 1410 bp long SacI-SacI fragment of
sIGF-II gene sequence from position 3912 and extending to the ¢rst
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intron was subcloned into the pALTER vector and used for subse-
quent mutagenesis. The nucleotide sequences of oligonucleotides used
in site-directed mutagenesis are indicated above; nucleotides in bold
represent mismatches with the actual sIGF-II sequences. Expression
constructs containing the mutated HNF-3L sites were made by sub-
cloning PCR fragments obtained by using primers APDIR and
APREV5 into the BamHI and NcoI sites of the pSla3 vector. All
mutant constructs were checked by sequencing.
For cotransfection experiments we used expression vectors encoding
full-length HNF-3K, HNF-3L, or HNF-3Q (kind gifts of Dr. G.R.
Crabtree, Stanford University, USA), and for electrophoretic mobility
shift assay (EMSA) experiments pGEX-HNF-3L (Dr. R.H. Costa,
University of Illinois, Chicago, USA).
2.4. Electrophoretic mobility shift assays
GST fusion protein containing the DNA binding domain of HNF-
3L fused to the glutathione S-transferase domain, GST-HNF-3L, was
overexpressed in E. coli and puri¢ed from bacterial extracts using
glutathione agarose beads [13]. The DNA fragments used in the
EMSA experiments determining the HNF-3 binding sites location
were labeled by ¢lling in 5P-protruding ends by using [K-32P]dCTP
and Klenow DNA polymerase. Double-stranded (ds) oligonucleotides
used in EMSAs were produced by annealing oligonucleotides
AP3HNF3 and AP3RHNF3, AP4HNF3 and AP4RHNF3,
AP5HNF3 and AP5RHNF3, APMAB and APMABR, APMBC
and APMBCR, respectively, and puri¢ed from a polyacrylamide gel.
Probes were labeled using [Q-32P]dATP and T4 polynucleotide kinase,
and puri¢ed over a Sephadex G-50 column.
Conditions for EMSA experiments were as described [14]. Brie£y,
binding reactions were performed by mixing 104 cpm of ds DNA
probe, competitor DNA and binding bu¡er, after which protein ex-
tract was added. Binding reactions were incubated for 45^60 min on
ice. DNA-protein complexes were separated on a 5% (37.5:1 (wt/wt)
acrylamide:bisacrylamide) polyacrylamide gel. Gels were dried and
exposed on Fuji XR ¢lms at 370‡C.
2.5. Transient transfections
Transient transfections of Hep3B human hepatoma cells [15] and
293 adenovirus transformed human kidney cells [16] were performed
by a modi¢ed calcium phosphate procedure using BES bu¡ered saline
[17]. Brie£y, cells were grown in 25 cm2 £asks to 60% con£uence and
transfected with 3 Wg of luciferase construct for 293 cells or 4.5 Wg of
construct for Hep3B cells and 0.5 Wg pCMV-LacZ to correct for
transfection e⁄ciencies. For cotransfections, pCMV-HNF3L or empty
CMV vector was added. Four h after transfection, Hep3B cells were
shocked with medium containing 10% dimethylsulfoxide, and both
cell lines received fresh medium. Cells were harvested 28 h after trans-
fection and luciferase and L-galactosidase assays were performed as
described in [17]. All transfection experiments were performed at least
three independent times in duplicate.
3. Results
3.1. HNF-3L transactivates the sIGF-II promoter
Previously, the activity of the salmon IGF-II promoter was
assayed in Hep3B and 293 cells, using transient transfection
assays. From these results it was determined that maximal
promoter activity was present in the pSla900 construct, con-
taining promoter sequences from 3912 to 34 relative to the
ATG start codon, coupled to the ¢re£y luciferase reporter
gene [4]. Using pSla900 in transient cotransfection experi-
ments we examined the putative transactivational properties
of three variants of HNF-3: HNF-3K, HNF-3L, and HNF-3Q
in the regulation of the sIGF-II promoter. Cotransfection of
293 cells with construct pSla900 and expression vectors encod-
ing either HNF-3K or HNF-3Q resulted in a 1- to 2-fold en-
hancement of pSla900 activity, whereas HNF-3L stimulated
pSla900 activity 6-fold. From these experiments it can be con-
cluded that HNF-3L is an activator of the sIGF-II promoter.
To further localize the putative HNF-3L sites additional trun-
cations of the promoter were tested and the smallest construct
that still conferred full activation by HNF-3L was pSla300
(Table 1). This suggests that putative HNF-3L responsive el-
ements are located in the ¢rst 300 nucleotides upstream of the
translation initiation codon of the sIGF-II gene.
3.2. The salmon IGF-II promoter contains three HNF-3 binding
sites
To con¢rm that HNF-3L binds to the region between 3299
and 34 relative to the translation initiation codon, electro-
phoretic mobility shift assays (EMSA) were performed. A
350 bp XbaI-XbaI DNA fragment from the pSla300 construct
representing the region from positions 3299 to 34 as well as
the ¢rst 49 bp of the luciferase gene was used as a probe and
incubated with increasing amounts of bacterially expressed
GST-HNF-3L. A single complex can be detected (Fig. 1, lanes
2^4), suggesting that HNF-3L forms a complex with this
DNA fragment. To con¢rm that the complex indeed repre-
sents binding of HNF-3L, a ds oligonucleotide harboring the
high a⁄nity HNF-3 binding site from the transthyretin pro-
moter (TTR-S) [18], was added in increasing amounts in a
competition EMSA (Fig. 1, lanes 6^8). TTR-S e¡ectively com-
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Table 1
E¡ects of mutated HNF-3L sites on sIGF-II gene transactivation
Construct Cell line
Hep3B 293
Fold activation by HNF-3L
pSla300 2.6 þ 0.3 5.3 þ 0.3
p300mutA 2.4 þ 0.2 3.7 þ 0.3
p300mutBC 1.5 þ 0.2 1.5 þ 0.2
Transient transfection experiments with wild-type (pSla300) and
HNF-3L mutant reporter constructs in Hep3B and 293 cells. The
basal transcriptional level of each reporter construct was set to 1,
and the fold activation by HNF-3L of the wild-type and mutant con-
structs are indicated. Each number represents the average of at least
three independent transfection experiments performed in duplicate.
The standard deviation is indicated.
Fig. 1. HNF-3L binds to the proximal promoter region of the
sIGF-II gene. Left panel (lanes 1^4): EMSA experiment with GST-
HNF-3L protein. Lane 1, probe only; wedges (lanes 2^4) represent
increasing amounts of GST-HNF-3L protein. Right panel (lanes 5^
8): Competition EMSA with the 3299/34 region of the sIGF-II
gene as a probe, a constant amount of GST-HNF-3L protein (lane
5) and increasing amounts of cold competitor oligonucleotide, con-
taining the strong HNF-3 binding site from the TTR promoter
(TTR-S) (lanes 6^8). FP, free probe.
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petes with the sIGF-II fragment for HNF-3L binding, indicat-
ing that HNF-3L forms a speci¢c DNA-protein complex with
the salmon IGF-II promoter region.
To further de¢ne the positions of the HNF-3L binding sites,
subfragments were tested in similar EMSA experiments
(Fig. 2). Using the restriction sites for MvaI (3119) and
NspI (3211), respectively, four fragments were gel separated,
puri¢ed and used in EMSA experiments simultaneously with
the whole XbaI-XbaI fragment (Fig. 2). This experiment
shows that the HNF-3L binding sites are located in the
most 3P-part of the promoter between positions 3119 and
+52 relative to the luciferase translation start codon (Fig. 2).
Comparison of the nucleotide sequence of this region with
the HNF-3 consensus binding sequence 5P-WRRRYMAA-
YA-3P (W = A/T, R = A/G, Y = C/T, M = A/C), as described
by [19], reveals three potential HNF-3 binding sites situated in
the sIGF-II-speci¢c part of the MvaI-XbaI fragment (Table
2). Since all three potential HNF-3 binding sites contained
two mismatches to the consensus HNF-3 binding sequence,
we checked whether any of these sites was capable of binding
to HNF-3L. Three ds oligonucleotides dsA, dsB, dsC, each
covering one of the putative binding sites were synthesized
and used as probes for HNF-3 binding in EMSA experiments
(Fig. 3, lanes 1^9). Incubation of the three probes with in-
creasing amounts of GST-HNF-3L resulted in distinct com-
plex formation. This suggests that all three ds oligonucleotides
are capable of binding HNF-3L, and that all three sites may
be functional in transactivation of the sIGF-II promoter
(Fig. 3).
3.3. Three HNF-3L binding sites are required for maximal
activation of the sIGF-II promoter
To establish the functional importance of the three identi-
¢ed HNF-3L binding sites in transactivation of the sIGF-II
promoter, the HNF-3 sites were mutated. Four point muta-
tions were introduced in each of the sites as follows: the
HNF-3L site A sequence 5P-TCACTCAACA-3P was altered
to 5P-TCACGGGGCA-3P, site B sequence 5P-TGGGAAAC-
TA-3P was altered to 5P-TGGGGGGGTA-3P, and site C se-
quence 5P-CAACCAAATA-3P was altered to 5P-CAACGGG-
GTA-3P. To prove that the introduced mutations could
completely abolish HNF-3L binding, EMSA experiments
were performed with GST-HNF-3L and the mutated oligos
as probes (Fig. 3, lanes 13^18). Mutation of sites A and B
(dsABm), as well as mutation of sites B and C (dsBCm) com-
pletely abolished HNF-3L binding. Thus, introduction of the
point mutations prevents the formation of HNF-3L-speci¢c
DNA-protein complexes (Fig. 3, lanes 13^18).
Finally, to check the functional role of the HNF-3L binding
sites, two reporter constructs were made. Because sites B and
FEBS 21687 15-3-99
Table 2
Interspecies comparison of the transcription start site and the three HNF-3 binding sites of known ¢sh IGF-II genes
Species Sequence
Tss region Site A Site B Site C
(3129 to 3121) (3100 to 391) (370 to 361) (342 to 333)
Chum salmon [4] 5P- GCCTGTCGC TcAcTCAACA TGGaAAcTA cAAcCAAATA -3P
Rainbow trout [7] 5P- GCCTGTCGC TcAcTCAACA TGGaAAcTA cAAcCAAATA -3P
Tilapia [6] 5P- GCCTGTCGC TcAcTCACCA TGGaAAcTA cAAcCAAATA -3P
Barramundi [5] 5P- GCCTGTCGC TcAcACATCA TGGaAAcTA cAAcCAAATA -3P
Pu¡er¢sha 5P- GCCTGTCGC TcATACATCA TGGaAAcTA cGAcCAAATC -3P
HNF-3 consensus WRRRYMAAYA WRRRYMAAYA WRRRYMAAYA
Positions of the HNF-3L binding sites of the salmon IGF-II gene are indicated relative to the A residue of the translation initiation codon.
Mismatches in the chum salmon sequence to the consensus HNF-3L binding sites are given in lower case. The sequences of the region around the
transcription start site and of the three HNF-3L sites from ¢ve ¢sh IGF-II genes are compared and di¡erences with the chum salmon gene are
indicated (italics). The putative transcription start site is underlined.
aSequence obtained from Genbank, accession number AL021880.
Fig. 2. Localization of HNF-3L binding sites in the sIGF-II pro-
moter by EMSA experiments. A: Top part: Schematic representa-
tion of the XbaI-XbaI fragment from pSla300 containing the region
from 3299 to 34 of the salmon IGF-II gene relative to the A resi-
due of translation initiation codon. The position of the putative
transcription start site (3125) is shown by an arrow and the posi-
tions of the NspI and MvaI restriction sites are indicated. The vec-
tor-speci¢c parts are shown as striped boxes. Lower part: Frag-
ments used in the EMSA analysis. + indicates that speci¢c DNA-
HNF-3L complexes are formed; 3 indicates that no binding of
GST-HNF-3L is observed. B: EMSAs with ¢ve sIGF-II-speci¢c
fragments. Lanes 1, 4, 7, 10, and 13 contain no protein and wedges
indicate increasing amounts of GST-HNF-3L used in EMSAs.
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C are well conserved among di¡erent ¢sh IGF-II genes (Table
2), both sites were mutated simultaneously in construct
p300mutBC. In addition, to check the contribution of the
less conserved site A, a single mutation was introduced in
construct p300mutA. The reporter constructs were tested in
transient cotransfection experiments with HNF-3L expression
vector in 293 and Hep3B cells (Table 1). The transactivation
by HNF-3L of the two mutated reporter constructs was lower
than that of the wild-type reporter construct in both cell lines
tested. While enhancement of the HNF-3L activity was mod-
erately impaired when site A was mutated, a more drastic
decrease in HNF-3L transactivation was observed for the mu-
tation of sites B and C. From these results we can conclude
that all three HNF-3L sites contribute to the transactivation
of the salmon IGF-II promoter by HNF-3L, but that sites B
and C have a relatively stronger in£uence on transcription
than site A.
4. Discussion
Previously, we determined the structure of the sIGF-II gene
and localized the transcription start site between positions
3140 and 3110 relative to the A residue of the translation
initiation codon [4]. Since then, the characterization of other
¢sh IGF-II genes has been described and the structures and
sequences of these genes are highly homologous. Transcrip-
tion start sites for the rainbow trout IGF-II gene were deter-
mined at positions 3124 and 3125, as well as further up-
stream [7], and a single transcription start site for the tilapia
IGF-II gene was found at the G residue at position 3125 [6].
Based on these data and our previous results, and given the
extremely high homology of this region (Table 2), it is very
probable that the transcription start site of the salmon IGF-II
gene is also located at position 3125.
In this study, three functional HNF-3L binding sites were
determined. It was shown that recombinant HNF-3L binds to
the three sites and that mutation of these binding sites com-
pletely abolishes the HNF-3L binding. Interestingly, all sites
are located within the 5P-UTR of the IGF-II gene. When
comparing the nucleotide sequence of the promoter/5P-UTR
of the IGF-II gene of several ¢sh species, it is clear that the
highest homology is found in the ¢rst 200 nucleotides up-
stream of the translation initiation codon. Only 60 nucleotides
upstream of the TATA-box are conserved and further up-
stream, sequences deviate rapidly. However, of the three func-
tional HNF-3L sites in salmon, two (B and C) are well con-
served (Table 2), suggesting that HNF-3L can be a regulator
of the IGF-II genes of other ¢sh species as well.
The presence of transcription factor binding sites down-
stream of the transcription start site is not exceptional. For
instance, promoter P3 of the human IGF-II gene was shown
to possess a functional binding site for the tumor suppressor
gene product WT1 around position +60, relative to the tran-
scription start site. Binding of WT1 represses the transactiva-
tion, whereas mutation of the WT1 site enhances promoter
activity 2.5-fold [20]. In addition, for the human IGF-I gene
two functional HNF-3L sites were identi¢ed, one of which is
located downstream of the transcription start site [21].
Liver is the major source for IGF-II in salmonids and high
IGF-II mRNA levels are maintained into adulthood. In fact,
the levels of IGF-II in rainbow trout are two times higher in
the adult liver than in the juvenile liver [22]. This suggests the
involvement of liver-enriched transcription factors playing a
role in the transactivation of the IGF-II gene. In ¢sh, Axial is
expressed in the very early stage of development, decreases
somewhat during later stages of embryogenesis, and was
shown to be present in adult zebra¢sh liver and gut [10].
Additionally, we checked for the presence of Axial in adult
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Fig. 3. Mutation of the HNF-3L binding sites abolishes HNF-3L binding. Left panel: EMSAs with ds oligonucleotides each representing one
of the three wild-type HNF-3L binding sites (A, B, and C) and increasing amounts of GST-HNF-3L. Lanes 1, 4 and 7: no protein added.
Right panel: EMSAs with ds oligonucleotides representing the wild-type HNF-3L binding site C (lanes 10^12), and ds oligonucleotides with
mutated sites A and B (lanes 13^15) or mutated sites B and C (lanes 16^18) and increasing amounts of GST-HNF-3L. Lanes 10, 13, and 16,
no protein added. FP, free probe.
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salmon liver poly(A) RNA using Northern blotting, and we
could con¢rm the presence of a 1.9 kb Axial/HNF-3-speci¢c
transcript (data not shown).
To test the ability of HNF-3L to induce activity of the
sIGF-II promoter, transfection studies were carried out in
the human liver-derived Hep3B cell line and the human 293
kidney cell line. The dedi¡erentiated Hep3B liver cells do pro-
duce some HNF-3L, but introduction of an HNF-3L expres-
sion vector is required to fully reconstitute the synthesis of the
liver-speci¢c factor HNF-3L. Introduction of the transcription
factor and the sIGF-II reporter construct into these cells al-
lows the comparison of the activities of the promoter con-
struct in the presence and absence of HNF-3L. In this study
rat HNF-3L was shown to structurally interact and function-
ally transactivate the salmon IGF-II promoter. The zebra¢sh
ortholog of the HNF-3L transcription factor, Axial, was
shown to be highly homologous in its DNA binding domain
as well as in its transactivation properties [11]. In view of this
highly structural and functional conservation among ¢sh and
mammals we surmise that the e¡ect of rat HNF-3L on the
salmon IGF-II gene promoter will be identical to that of the
homologous ¢sh transcription factor Axial.
Mutational analysis of the three HNF-3L sites in the sIGF-
II reporter constructs was performed and the e¡ects on pro-
moter activity were assayed. Mutation of site A or sites B and
C reduced transactivation by HNF-3L to 70% and 25%, re-
spectively in 293 cells, and to 92% and 57% in Hep3B cells.
From this we can conclude that mutations in sites B and C
severely impair transactivation by HNF-3L, whereas site A
mutations only slightly reduce the activation by HNF-3L.
The stimulating e¡ect of HNF-3L on sIGF-II transcription
is higher in 293 cells than in Hep3B cells. This phenomenon
can be explained by the fact that 293 cells do not express any
endogenous HNF-3L, whereas Hep3B cells already contain
endogenously expressed HNF-3L. Therefore, the fold activa-
tion due to cotransfection of exogenous HNF-3L will be lower
in Hep3B cells than in 293 cells, since the basal level of pro-
moter activity is already somewhat stimulated by HNF-3L in
Hep3B cells.
In summary, in this study we have shown for the ¢rst time
that a liver-enriched transcription factor can activate sIGF-II
gene transcription. This explains, at least partially, the high
levels of IGF-II not only during early development, but also
in the juvenile and adult salmon.
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